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Abstract
Background: Intrauterine growth restriction (IUGR) is associated with perinatal morbidity and mortality. Several
clinical trials have reported L-arginine and sildenafil citrate had effect on intrauterine growth restriction fetuses. A
meta-analysis of available randomized controlled trials (RCTs) was conducted to investigate the effects of L-arginine
and sildenafil citrate on major clinical outcomes of IUGR fetuses.
Methods: Systematically searched Medline, Embase, the Cochrane Library, and Clinical Trials, references of retrieved
articles, and conference proceedings from 1960 to 2015. We included randomized controlled trials assessing the
effects of L-arginine and sildenafil citrate on IUGR. Outcomes analyzed were the birth weight, gestational age at
labor, Apgar score at 1and 5 min, the ratio of NRDS, the ratio of ICH and neonatal death, etc.
Results: Ten trials were included. Nine trials (576 patients) compared L-arginine with either placebo or no intervention.
In the L-arginine treatment groups of the L-arginine trials, there was a significant increase in fetal birth weight (SMD 0.
41, 95 % CI [0.24,0.58]), gestational age (SMD 0.30, 95 % CI [0.07,0.54]); L-arginine treatment group have a significant
reduction in the ratio of neonatal respiratory distress syndrome (P = 0.009), intracranial hemorrhage of fetuses (P = 0.
002), but the number of included studies and people on these outcomes are small. As only one trial (41 patients)
compared sildenafil citrate with placebo, it was too small for reliable conclusions about possible differential effects
could be drawn.
Conclusions: The results of this meta-analysis showed that L-arginine increased birth weight and prolonged
gestational age at labor of IUGR fetuses. However, further large-scale RCTs are needed to adequately assess the
effect of L-arginine and Sildenafil citrate on clinical outcomes, because the number of study may be small.
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Background
Fetal development represents a critical period in
humans, and can influences adult phenotypes. Intrauter-
ine growth restriction (IUGR), a condition in which the
fetus is pathologically growth restricted in uterus, re-
mains a serious public health problem. Although the
term is often used interchangeably with small for gesta-
tional age (SGA), which refers to for infants with birth
weights below the 10th percentile for the gestational age.
IUGR is estimated to occur in 5 to 7 % of all pregnancies
[1]. The most common cause of IUGR is placenta-
vascular insufficiency. Many studies have shown that
IUGR is associated with increased risk of premature
birth, reduced neonatal survival and long-term sequelae
(including impaired neuro-developmental progress in
childhood and insulin-resistance in adulthood) [2].
Nitric oxide (NO) is produced by nitric oxide synthases
(NOS) using the amino acid L-arginine as substrate. Then
NO diffuses into adjacent vascular smooth muscle cells
and increases the concentration of second-messenger cyc-
lic guanosine monophosphate (cGMP), resulting in the re-
laxation of vascular smooth muscle. In a normal pregnant
woman, NO plays an important role in increasing the
oxygen and nutrient supply to the fetus by influencing
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vasodilatation in feto-placental circulation. Reduced NO
availability may have an important role in the pathophysi-
ology of IUGR [3]; previous data suggest that IUGR could
be induced by blocking NO synthesis [4]. Therefore, NO
donors (glyceryl trinitrate and isosorbide mononitrate),
precursors (L-arginine) and NO mediator (sildenafil cit-
rate and vardenafil) may be possible therapeutic ap-
proaches for IUGR. In these NO agents, L-arginine or
sildenafil citrate supplementation in pregnancy has re-
cently been applied to manage IUGR and its complica-
tions in many clinical studies.
L-arginine is an amino acid that is essential to the
body’s production of NO. However, many studies had
shown that preterm infants and pregnant women could
present with arginine deficiency [5, 6], and impaired ar-
ginine transport into endothelial cells was observed in
the umbilical endothelium from IUGR infants [7]. Sil-
denafil citrate, a phosphodiesterase inhibitor (PDE5-se-
lective inhibitor) that enhances the effects of NO, acts
by blocking the enzymes that break down cGMP, which
mediates the effects of NO in the body and leads to vas-
cular relaxation.
Some studies had shown that the use of L-arginine
and sildenafil citrate appeared effective. However, other
clinical trials completed in the past few years presented
uncertain results. Therefore, we carried out a systematic
review and meta-analysis to investigate the effects of
L-arginine and sildenafil citrate on clinical outcomes
of IUGR.
Methods
In October 2015 we searched Medline (from 1966 to
October 2015), Embase (from 1974 to October 2015),
the Cochrane Library database (Cochrane Central
Register of Controlled Trials) and Clinical Trials
(October 2015); The search terms that were used to
searched original articles included “sildenafil citrate”, “L-
arginine”,”arginine”, “intrauterine growth restriction”,
“fetal growth restriction”, “small for gestational age”, and
“low birth weight”. These search terms were combined
according to the need of the study. Reference lists from
identified trials and review articles also were manually
scanned to identify any other relevant studies. We did
not apply any language restrictions.
The literature was reviewed to select studies that met
the following inclusion criteria: 1) randomized or quasi-
randomized controlled trials. 2) Pregnant woman with a
singleton pregnancy, whose fetus had been diagnosed
with IUGR, according to reference values. 3) Studies that
were compared of L-arginine or sildenafil citrate with
placebo or no intervention. Studies were excluded if they
did not meet all of these inclusion criteria.
Study selection: First, two authors (JC-C and PY-C) in-
dependently screened the search results to confirm
citations with potential relevance. Second, we obtained
the full text with potential relevance. Two authors (JC-C
and PY-C) independently decided on trial inclusion. We
resolved any differences in opinion by discussion.
Assessment of study quality: Both review authors inde-
pendently assessed the quality of each trial using the cri-
teria outlined in Cochrance Handbook for Systematic
Reviews of Interventions. Study quality was judged by
the design and execution of randomization, concealment
of allocation, completeness of follow up and blinding.
Statistical calculations were performed using the com-
puter programs STATA 12 statistical software (STATA
corp, Tex). For dichotomous data, we presented results
as risk ratios (RRs) with 95 % confidence intervals (95 %
CIs). Data were combined for a meta-analysis to
calculate a pooled estimate of a treatment effect for each
outcome. For continuous data, we reported the stan-
dardized mean difference (SMD). Summary estimates of
SMDs or RRs were obtained with a random effects
model. An I2 statistic was used to assess heterogeneity
between trials. Heterogeneity was determined by a ran-
dom effects model. If substantial heterogeneity was
found in updates (I2 more than 50 %), subgroup analyses
for main outcomes were performed. Potential publica-
tion bias was assessed with Egger’s test. A two-sided P
value less than 0.05 was regarded as significant differ-
ence for all analyses.
Results
L-arginine on IUGR
The literature search yielded 1871 articles, of which
57 full texts were reviewed; the process was shown in
Additional file 1. Of these studies, 8 randomized con-
trolled trials and one quasi-randomized controlled
trial [8] met the inclusion criteria. The number of pa-
tients in each trial ranged from 41 to 108 and totaled
576. However, two studies did not specify the number
of IUGRs during pregnancy and one study only indi-
cated a ratio of IUGR [9]. Other studies specified
IUGR after a fetus had been delivered. In these trials,
the expected fetal body weight between the control/
placebo groups and arginine treatment groups were
similar by ultrasound when they entered the study.
The gestational ages at the beginning of treatment
and at delivery are listed in Table 1. One study diag-
nosed IUGR in the mid-trimester, IUGR in this study
was related to severe IUGR [10].
We assessed the quality of each trial using the criteria
outlined in Cochrance Handbook for Systematic Reviews
of Interventions, the data were shown in Additional file
2. Overall, five studies were of good quality, and four
were of uncertain quality.
The effects of L-arginine treatment on birth weight
were shown in Fig. 1. Birth weight was the most
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important marker in evaluating the effect of L-arginine
on IUGR. When data from all the studies were com-
bined, the overall SMD was 0.41, (95 % CI [0.24, 0.58],
P < 0.0001, heterogeneity: I2 = 0, P = 0.909). This indi-
cated that the birth weight of IUGR fetuses significantly
increased after arginine treatment.
The effects of L-arginine therapy on gestational age at
labor were shown in Fig. 2. Data on gestational age at
labour were available for 7 trials. In these 7 trials, the
fetuses were full-term births in one study [8] and
preterm in the other studies. The combined SMD for
gestational age at labor was 0.30, 95 % CI [0.07,
Table 1 Characteristics of 9 studies eligible for inclusion in meta-analysis
Studies ARG/PG (or
control group)













et al. 2004 [14]
78/30 Below 10th percentile
for GA
NA 27.1 ± 5.2/
29.5 ± 7.4
29.5 ± 2.7/31.7 ± 3.6 3 g/d, oral 20 days
Xiao and Li
2005 [8]
30/36 Below 10th percentile
for GA
NA 27.0 ± 3.6/
27.4 ± 3.1





30/31 Below 10th percentile
for GA
preeclampsia 29.3 ± 6.7/
29.2 ± 5.9












24/17 Below 10th percentile
for GA
NA 28.7 ± 5.9/
28.7 ± 3.8























30/30 Below 10th percentile
for GA





30/30 Below 10th percentile
for GA
NA 25.47 ± 4.3/
25.17 ± 4.3
33.13 ± 2.9/33.0 ± 2.3 3 g/d, oral 21 days
ARG L-Arginine treatment group, PG placebo group, GA gestational age, NA not available
Fig. 1 Random-effetcs meta-analysis comparing birth weight between control groups and L-aginine groups. The test for heterogeneity was not
significant (P = 0.91),the standardized mean difference significantly favors controls (0.41, 95 % CI [0.24, 0.58], P < 0.0001)
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0.51], P = 0.012, heterogeneity: I2 = 31.6 %, P = 0.187.
There was a significant difference between the two
groups.
Table 2 summarizes other clinical outcomes (including
the ratio of neonatal respiratory distress syndrome
(NRDS) and intracranial hemorrhage (ICH), Apgar score
at 1 and 5 min),and neonatal death. The ratio of NRDS
was available for 4 trials [8, 9, 12, 16]. Compared with
the control/placebo group, the ratio of NRDS in the
treatment group was significantly reduced. The com-
bined RR was 0.49, 95 % CI [0.29, 0.84], P = 0.009. Het-
erogeneity: I2 = 48 %, P for heterogeneity = 0.13. Two
trials reported the ratio of ICH [8, 12]. Compared with
the placebo group, the ratio of ICH in the treatment
group was significantly reduced. The combined RR was
0.13, 95 % CI [0.03, 0.48], P = 0.002, heterogeneity: I2 =
0 %, P for heterogeneity = 0.90.
The effects of arginine treatment on the Apgar score
(1 min, 5 min) in the individual studies are shown in
Table 2. In the Dera et al. [9] study, the authors only
reported the mean value and did not list the ratio of the
related Apgar score. Therefore, the statistical data were
not included in this study. The combined odds ratio for
the Apgar score at 1 min (Apgar score more than 7) was
RR 0.49, 95 % CI [0.23, 1.03], heterogeneity: I2 = 45 %, P
for overall effect = 0.06. The combined RR for the Apgar
score at 5 min was (Apgar score >7) 0.28, 95 % CI [007,
1.16] P = 0.08, heterogeneity: I2 = 67 %, P for heterogen-
eity = 0.05. Only two trial reported the ratio of neonatal
mortality [15, 16], the data show that there wasn’t sig-
nificant difference between the two groups (P = 0.80).
Table 3 summarizes the clinical outcomes from argin-
ine in pregnant women. Maternal and umbilical blood
serum levels of NO2/NO3 were available from 3 trials [8,
10, 11]. Compared to the control/placebo group, the
serum NO2/NO3 levels in the umbilical and maternal
blood of the treatment group was significantly different
(P < 0.0001). A Doppler evaluation of umbilical arteries
was available from 2 trials [11, 15]. Compared to the
control group, the pulsatility index (PI) was significantly
Fig. 2 Random-effetcs meta-analysis comparing gestational age at labour between control groups and L-aginine groups. The test for heterogen-
eity was not significant (P = 0.19),the standardized mean difference significantly favors controls (0.30, 95 % CI [0.07,0.54], P = 0.012)
Table 2 Outcomes that the effect of L-arginine on neonate
Included stuides (N) ARG/PG (or control group) Relative risk (95 % CI) P value for overall effect P value for heterogeneity
The ratio of NRDS 4 122/98 0.49 [0.29,0.84] 0.009 0.13
The ratio of ICH 2 66/44 0.13 [0.03,0.48] 0.002 0.90
Apgar score(>7) (1 min) 4 110/101 0.49 [0.23,1.03] 0.06 0.14
Apgar score(>7) (5 min) 4 101/94 0.28 [0.07,1.16] 0.08 0.05
Neonatal mortality 2 56/55 0.82 [0.19,3.66] 0.80 0.28
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lower in the umbilical artery after three weeks of treat-
ment (P = 0.02).
There was no evidence of publication bias for the
outcome of birth weight between two groups (Egger’s
test P = 0.70).
The number of included studies and people on clinical
outcomes (including the ratio of NRDS, ICH, Apgar
score and neonatal mortality) was small. Therefore, there
were insufficient data for reliable conclusions on the ef-
fects of L-arginine treatment on these clinical outcomes
of IUGR fetuses.
Effect of Sildenafil citrate on IUGR
Two trials compared Sildenafil citrate with either pla-
cebo or no intervention. One study [17] was a RCT, and
the other [18] was a nonrandomized comparative study.
The two trials both had positive outcomes (improve-
ments in umbilical and middle cerebral arteries Doppler
velocimetries). However, further analysis of the effect of
sildenafil citrate on IUGR was not possible because the
number of included trials was insufficient.
Discussion
Main findings
The aim of this meta-analysis was to assess the effective-
ness of L-arginine and sildenafil citrate for treating
IUGR. Ten small trials evaluated the effects of L-
arginine or sildenafil citrate compared with a placebo or
no intervention in women with an increased risk of
IUGR. The combined results suggest that L-arginine in-
creases fetal birth weight and prolong the gestational age
at labor. These findings are in contrast with results from
some review studies and individual trials that reported
no benefit with these therapies [19, 20]. As only one trial
compared sildenafil citrate with placebo on IUGR, no
reliable conclusions about possible differential effects
could be drawn.
Low birth weight is one of the most direct manifesta-
tions of IUGR, increased birth weight means the reduced
number of IUGR fetuses. In our analysis, L-arginine sig-
nificantly increased fetal birth weight (9 trials, SMD
0.41, 95 % CI [0.24, 0.58], P < 0.0001), and the arginine
treatment in IUGR was effective in 8 trials. Only one
study by Winer et al. reported negative results. However,
the included patients were different between Winer et al’
study and other 8 trials, the IUGR in Winer et al’ study
were severe IUGR, the infants also were very preterm
infants (gestational age < 32 weeks). The concentration
of L-arginine in pregnant women varied [21, 22]. A co-
hort study by Neri I et al. [23] evaluated pregnant
women with mild or moderate growth-restricted fetuses
and pregnant women with severe growth-restricted fe-
tuses. After these patients were given L-arginine, the
birth weight in the former group was significantly higher
than in the latter group (birth weight was 2061 g vs
1608 g). Different patients included may lead to different
outcomes in our meta-analysis. Regardless, more RCTs
are needed to address this possibility.
As we mentioned above, IUGR is associated with in-
creased risk of premature birth; prolonged latency (dur-
ation of pregnancy) results in a reduced rate of preterm
birth. Prematurity is usually accompanied by adverse
neonatal outcomes, such as NRDS, ICH, and low Apgar
score. At the same time, the weight of fetus increases
fastest during the third trimester of pregnancy, and
prolonged latency also may increase birth weight. Some
studies also showed IUGR was increased with prema-
turity (gestational age at labor 26 weeks = 8.9 %, 27
weeks = 7.7 %, 28 weeks = 9.8 %) [24]. In our study,
our results show that L-arginine can prolonged gesta-
tional age in our study, it don‘t significantly reduce
the rates of neonate mortality, and significantly in-
creased the Apgar score (P > 0.05). These results are
puzzling. We speculated that the included trials that
L-arginine on major clinical outcomes were too few
to reach consistent conclusions, so further studies are
needed.
When L-arginine is taken orally, 40 % is degraded
by the small intestine and metabolized by arginase in
the liver. Thus, poor arginine availability in the blood
may limit the efficacy of this amino acid [25, 26].
However, almost all studies in our study have positive
results, though the daily doses and courses of treat-
ment were different. The determination of the opti-
mal duration of L-arginine therapy requires further
research. In the oral groups, L-arginine was adminis-
tered until delivery; in the intravenous group, it was
given for 7 days, 14 days or 20 days. Rytlewski K et al.
[15] demonstrated a significant increase in estimated
fetal body weight after the first two weeks of treat-
ment in their L-arginine group compared to the pla-
cebo group. However, the results from other trials
were different [27, 28]. Therefore, more studies are
necessary to clarify these results.
Table 3 Clinical outcomes that arginine effect on pregnant women: study include, odds risk, heterogeneity
Studies SMD (95 %CI) P value
NO2/NO3 level in umbilical blood 3 0.66 [0.35,0.96] <0.0001
NO2/NO3 level in maternal blood 3 0.70 [0.39,1.00] <0.0001
Pulsatility indexes(PI) in umbilical artery 2 −1.98 [−3.65,−0.32] 0.02
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Some authors have reported some side effects of L-
arginine in other studies, such as diarrhea, disturbance
of acid–base balance, etc [29–31]. However, none of the
9 trials in this study described any L-arginine side ef-
fects. Additionally, no teratogenic or lethal effects were
reported. The number of included studies in our meta-
analysis is small, so it is imperative that future studies be
designed to address these side effects.
Animals studies had shown that L-arginine was benefi-
cial to IUGR and the other mechanisms of effect of ar-
ginine on fetus growth include: 1) Creatine. L-arginine
can produce creatine that is one of materials which
make form muscle. Arginine also can stimulate skeletal
muscle protein synthesis [32, 33]. 2) Growth hormone.
L-arginine is also found to improve growth hormone
releasing hormone secretion, and as a consequence in-
crease in plasmatic growth hormone influencing somatic
growth [34]. 3) L-arginine was reported to promote
polyamine synthesis that can enhance placental
growth and development [35]. 4) Arginine can stimu-
late insulin secretion, insulin is a major anabolic hor-
mone in the fetus [23].
As a vasodilator, sildenafil citrate can reduce vasocon-
striction and improve relaxation of IUGR myometrial
small arteries, which may improve oxygen and nutri-
tional supply to the fetus [36, 37]. Some experimental
studies have supported sildenafil citrate as a potential
candidate for the treatment of IUGR in both animals
and human [38–41]. However, there is limited clinical
information proving the efficacy of sildenafil in treating
IUGR. Therefore, more RCTs are needed to be designed
to determine the effect of sildenafil citrate on IUGR.
There were several limitations in our meta-analysis.
First, the number of included trials was very small, and
only one RCT that comparing sildenafil citrate with pla-
cebo was included. Second, the sample sizes of these
trials were quite small. Third, the dose and the route of
L-arginine administration varied, potentially leading to
uncertainty biases in the final result of the meta-analysis.
Conclusions
According to our meta-analysis, L-arginine supplemen-
tation is superior to placebo in increasing birth weight
and prolonging gestational age at labor of IUGR fetuses,
but the data for L-arginine on other clinical outcomes
(like the ratio of NRDS,ICH, Apgar score and neonatal
mortality) were insufficient. At this time, there is
insufficient evidence to draw conclusions about L-
arginine supplementation in IUGR. Large-scale, multi-
center RCTs are needed to determine whether arginine
supplementation has a beneficial role in IUGR disorders.
Only one trial compared sildenafil citrate with placebo,
There is limited information on the efficacy of sildenafil
citrate for treating IUGR.
Additional files
Additional file 1: Identification process for eligible studies. (DOC 35 kb)
Additional file 2: Quality of enrolled RCTs [8–16]. (DOC 40 kb)
Abbreviations
ICH, intracranial hemorrhage; IUGR, intrauterine growth restriction; NO, nitric
oxide; NRDS, neonatal respiratory distress syndrome; RCTs, randomized
controlled trials; RR, risk ratios; SGA, small for gestational age; SMD,
standardized mean difference
Acknowledgements
The authors thank Prof Dingan Mao for his advice on the meta-analyses and
Kaiju Luo for statistical advice.
Funding
The planned science and technology project of Hunan province (No.
2014SK4067).
Availability of data and materials
All data analyzed during this study are included in these published articles
(References [8–18]).
Authors’ contributions
The planning and design of the study was fulfilled by JC-C and PY-C. JC-C,
XQ-Z and TB contributed to the acquisition of data, and were charged with
the initial analysis and interpretation of data. All authors assisted in drafting
and revising the manuscript. All authors have approved the final version of
the article for publication.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Division of Neonatology, The Second Xiangya Hospital, Central South
University, 139 Renmin Middle Rd, Changsha, Hunan 410011, China.
2Department Obstetrics and Gynecology and Reproductive Genetics,
University of Utah, Salt Lake City, UT 84132, USA.
Received: 19 January 2016 Accepted: 4 August 2016
References
1. Suhag A, Berghella V. Intrauterine Growth Restriction (IUGR): etiology and
diagnosis. Curr Obstet Gynecol Rep. 2013;2:102–11.
2. Figueras F, Gardosi J. Intrauterine growth restriction: new concepts in
antenatal surveillance, diagnosis, and management. Am J Obstet Gynecol
(AJOG). 2011;204:288–300.
3. Myatt L, Eis AL, Brockman DE, Greer IA, Lyall F. Endothelial nitric oxide
synthase in placental villous tissue from normal, pre-eclamptic and
intrauterine growth restricted pregnancies. Hum Reprod. 1997;12:167–72.
4. Diaz V, Lebras-Isabet MN, Denjean A. Effect of Nomega-nitro-L-arginine
methyl ester-induced intrauterine growth restriction on postnatal lung
growth in rats. Pediatr Res. 2005;58:557–61.
5. Morris N, Eaton BM. Nitric oxide, the endothelium, pregnancy and pre-
eclampsia. Br J Obstet Gynaecol. 1996;103:4–15.
6. Becker RM, Wu G, Galanko JA, Chen WN, Maynor AR, Bose CL, et al.
Reduced serum amino acid concentrations in infants with necrotizing
enterocolitis. J Pediatr. 2000;137:785–93.
7. Casanello P, Sobrevia L. Intrauterine growth retardation is associated with
reduced activity and expression of the cationic amino acid transport
systems yþ/hCAT-1 and yþ/hCAT-2B and lower activity of nitric oxide
synthase in human umbilical vein endothelial cells. Circ Res. 2002;91:127–34.
Chen et al. BMC Pregnancy and Childbirth  (2016) 16:225 Page 6 of 7
8. Xiao XM, Li LM. L-Arginine treatment for asymmetric fetal growth restriction.
Int J Gynecol Obstet. 2005;88:15–8.
9. Dera A, Ropacka M, Kowalska J, Markwitz W, Nycz P, Breborowicz GH. The
effect of L-arginine treatment on the neonatal outcome from pregnancies
complicated by intrauterine growth restriction and gestational
hypertension. Arch Perinat Med. 2007;13:35–9.
10. Winer N, Branger B, Azria E, Tsatsaris V, Philippe HJ, Roze JC, et al. L-Arginine
treatment for severe vascular fetal intrauterine growth restriction: a
randomized double-bind controlled trial. Clin Nutr. 2009;28:243–8.
11. Zhang N, Xiong AH, Xiao X, Li LP. Effect and mechanism of L-arginine
therapy for fetal growth retardation due to pregnancy-induced
hypertension. J South Med Univ. 2007;27:198–200.
12. Ropacka M, Kowalska J, Hepner KB, Markwitz W, Breborowicz GH. The effect of
L-arginine on fetal outcome in IUGR fetuses. Arch Perinat Med. 2007;13:30–4.
13. Shen SF, Hua CH. Effect of L-arginine on the expression of Bcl-2 and Bax in
the placenta of fetal growth restriction. J Matern Fetal Neonatal Med. 2011;
24:822–6.
14. Sieroszewski P, Suzin J, Bilińska AK. Utrasound evaluation of intrauterine
growth restriction therapy by a nitric oxide donor (L-arginine). J Matern
Fetal Neonatal Med. 2004;15:363–6.
15. Rytlewski K, Olszanecki R, Lauterbach R, Grzyb A, Basta A. Effects of oral L-
Arginine on the foetal condition and neonatal outcome in preeclampsia.
BCPT. 2006;99:146–52.
16. Singh S, Singh A, Sharma D, Singh A, Narula MK, Bhattacharjee J.
Effect of l-arginine on nitric oxide levels in intrauterine growth
restriction and its correlation with fetal outcome. Indian J Clin
Biochem. 2015;30:298–304.
17. Dastjerdi MV, Hosseini S, Bayani L. Sildenafil citrate and uteroplacental
perfusion in fetal growth restriction. J Res Med Sci. 2012;17:632–6.
18. von Dadelszen P, Dwinnell S, Magee LA, Carleton BC, Gruslin A, Lee B,
et al. Sildenafil citrate therapy for severe early-onset intrauterine growth
restriction. BJOG. 2011;118:624–8.
19. Gui SF, Jia J, Niu XY, Bai X, Zou H, Deng J, et al. Arginine supplementation
for improving maternal and neonatal outcomes in hypertensive disorder
of pregnancy: a systematic review. J Renin Angiotensin Aldosterone Syst.
2014;15:88–96.
20. Vadillo-Ortega F, Perichart-Perera O, Espino S, Marco AV, Isabel I,
Roberto A, et al. Effect of supplementation during pregnancy with L-
arginine and antioxidant vitamins in medical food on pre-eclampsia
in high risk population: randomised controlled trial. BMJ. 2011;342:
d2901.
21. Benedtto C, Marozio L, Neri I, Giarola M, Vlope A, Facchinetti F.
Increased l-citrulline/l-arginine plasma ratio in severe preeclampsia.
Obstet Gynecol. 2000;96:395–9.
22. Bode-Böger SM, Scalera F, Ignarro LJ. The L-arginine paradox: importance of
the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther. 2007;
114:295–306.
23. Neri I, Mazza V, Galassi MC, Volpe A, Facchinetti F. Effects of L-arginine on
utero-placental circulation in growth-retarded fetuses. Acta Obstet Gynecol
Scand. 1996;75:208–12.
24. Facchinetti F, Longo M, Piccinini F, Neri I, Volpe A. L-arginine infusion
reduces blood pressure in preeclamptic women through nitric oxide
release. J Soc Gynecol Investig. 1999;6:202–7.
25. Wu G, Bazer FW, Cudd TA, Jobgen WS, Kim SW, Lassala A, et al. Pharmacokinetics
and safety of arginine supplementation in animals. J Nutr. 2007;137:1673S–80.
26. Curis E, Nicolis I, Moinard C, Osowska S, Zerrouk N, Be´nazeth S. Almost all
about citrulline in mammals. Amino Acids. 2005;29:177–205.
27. Staff AC, Berge L, Haugen G, Lorentzen B, Mikkelsen B, Henriksen T. Dietary
supplementation with L-arginine or placebo in women with pre-eclampsia.
Acta Obstet Gynecol Scand. 2004;83:103–7.
28. Germain AM, Valdez G, Romanik MC, Reyes S. Letter to the editor: evidence
supporting a beneficial role for long term L-arginine supplementation in
high-risk pregnancies. Hypertension. 2004;44:e1.
29. Grimble GK. Adverse gastrointestinal effects of arginine and related amino
acids. J Nutr. 2007;137:1693S–701.
30. Hladunewich MA, Derby GC, Lafayette RA, Blouch KL, Druzin ML, Myers BD.
Effect of L-arginine therapy on the glomerular injury of preeclampsia: a
randomized controlled trial. Obstet Gynecol. 2006;107:886–95.
31. Wu G, Bazer FW, Davis TA, Kim SW, Li P, Marc Rhoads J, et al. Arginine
metabolism and nutrition in growth, health and disease. Amino Acids.
2009;37:153–68.
32. Lacassie HJ, Germain AM, Valdés G, Fernández MS, Allamand F, López H.
Management of Eisenmenger syndrome in pregnancy with sildenafil and L-
arginine. Obstet Gynecol. 2004;103:1118–20.
33. Kim SW, Wu G. Dietary arginine supplementation enhances the growth of
milk-fed young pigs. J Nutr. 2004;134:625–30.
34. de Boo HA, Eremia SC, Bloomfield FH, Oliver MH, Harding JE. Treatment of
intrauterine growth restriction with maternal growth hormone
supplementation in sheep. Am J Obstet Gynecol (AJOG). 2008;199:559. e1–e9.
35. Kwon H, Wu G, Bazer FW, Spencer TE. Developmental changes in polyamine
levels and synthesis in the ovine conceptus. Biol Reprod. 2003;69:1626–34.
36. Sher G, Fisch JD. Vaginal sildenafil (Viagra): a preliminary report of a novel
method to improve uterine artery blood flow and endometrial
development in patients undergoing IVF. Hum Reprod. 2000;15:806–9.
37. Wareing M, Myers JE, O’Hara M, Baker PN. Sildenafil citrate (Viagra) enhances
vasodilatation in fetal growth restriction. J Clin Endocrinol Metab. 2005;90:2550–5.
38. Belik J. Sildenafil administration during pregnancy increases fetal rat weight
gain. FASEB J. 2005;19:A1248.
39. Refuerzo JS, Sokol RJ, Aranda JV, Hallak M, Hotra JW, Kruger M, et al.
Sildenafil citrate and fetal outcome in pregnant rats. Fetal Diagn Ther. 2006;
21:259–63.
40. Paulus WE, Strehler E, Zhang M, Jelinkova L, El-Danasouri I, Sterzik K. Benefit
of vaginal sildenafil citrate in assisted reproduction therapy. Fertil Steril.
2002;77:846–7.
41. Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, et al. A
randomised, double-blinded, placebo-controlled study of the
phosphodiesterase type 5 inhibitor sildenafil for the treatment of
preeclampsia. Hypertens Pregnancy. 2009;28:369–82.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chen et al. BMC Pregnancy and Childbirth  (2016) 16:225 Page 7 of 7
